Table 3.
Complications according to first- line therapy
| HCT (76) | IST (226) | p-value | |
|---|---|---|---|
| Hemorrhage | 32 (42.1) | 127 (56.2) | 0.088 |
| Severe hemorrhage | 18 (56.25) | 63 (49.6) | 0.751 |
| Infection | 68 (89.5) | 205 (90.7) | 0.343 |
| Severe infection | 40 (58.8) | 105 (51.2) | 0.203 |
| Thromboembolic event | 5 (6.6) | 28 (12.4) | 0.201 |
| Iron overload | 3 (3.9) | 41 (18.1) | 0.002 |
| Cardiovascular event | 1 (1.3) | 24 (10.6) | 0.011 |
| Endocrine dysfunction | 1 (1.3) | 11 (4.9) | 0.17 |
| Aseptic osteonecrosis | 2 (2.6) | 6 (2.7) | 0.991 |
| Acute GvHD Grade 2-4 | 28 (36.8) | ||
| Resolved | 13 () | ||
| Chronic GvHD | 25 (32.9) | ||
| Limited | 17 (68) | ||
| Extensive | 8 (32) | ||
| Resolved | 11 (44) | ||
| MDS/AML | 1 (1.3) | 33 (14.6) | 0.004 |
| Secondary malignancy | 8 (10.5) | 17 (7.5) | 0.411 |
| Solid tumor | 5 | 11 | |
| Lymphoma | 2 | 2 | |
| Other/unknown | 1 | 4 |